Kushner David M, Connor Joseph P, Wilson Michael A, Hafez G Reza, Chappell Richard J, Stewart Sarah L, Hartenbach Ellen M
Gynecologic Oncology, Paul P. Carbone Comprehensive Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Gynecol Oncol. 2007 Sep;106(3):507-12. doi: 10.1016/j.ygyno.2007.04.031. Epub 2007 Jun 8.
To provide data from a US center on laparoscopic (LSC) approach to sentinel lymph node (SLN) detection in cervix cancer with detailed time analysis.
This prospective trial enrolled patients with stage IA2-IIA cervix cancer undergoing primary radical surgery. Tc-99 radiocolloid was injected the morning of surgery, followed by hybrid SPECT/CT lymphoscintigraphy. Blue dye injection occurred just prior to incision. After bilateral LSC SLN detection, all patients received complete LSC pelvic lymphadenectomy. Institutional SLN protocol was followed for frozen section, hematoxylin and eosin, and cytokeratin staining.
Between December 2003 and February 2006, 20 enrolled patients received 9 LSC-assisted radical vaginal hysterectomies, 7 radical abdominal hysterectomies, 2 LSC-assisted radical vaginal trachelectomies, and 2 LSC lymphadenectomies alone (secondary to positive lymph nodes). Mean tumor size was 2.5 cm. Nineteen percent of the 64 SLNs were found in unusual sites, including common iliac (11%), presacral (5%) and para-aortic (3%). The negative predictive value was 100%. The combined technique detected SLNs bilaterally in all patients. If blue dye alone was used, this rate would have dropped to 67.5% and was negatively correlated with elapsed surgical time (-0.7; p=0.002). The ability to visualize blue SLNs remained steady for 30 min and was completely gone by 50 min.
Laparoscopic SLN mapping can be newly introduced into gynecologic oncology centers with high detection rates and negative predictive values. The visualization of blue dye in SLNs is transient, and this negative time correlation may explain the previously reported inferior detection rates with this technique. CLINICAL TRIAL REGISTRATION.: ClinicalTrials.gov, http://www.clinicaltrials.gov, NCT 00205010.
提供美国一家中心关于腹腔镜(LSC)方法检测宫颈癌前哨淋巴结(SLN)的数据,并进行详细的时间分析。
这项前瞻性试验纳入了接受原发性根治性手术的IA2-IIA期宫颈癌患者。手术当天上午注射Tc-99放射性胶体,随后进行SPECT/CT混合淋巴闪烁显像。在切开前即刻注射蓝色染料。在双侧LSC检测SLN后,所有患者均接受完整的LSC盆腔淋巴结清扫术。按照机构的SLN方案进行冰冻切片、苏木精和伊红染色以及细胞角蛋白染色。
2003年12月至2006年2月期间,20例入组患者接受了9例LSC辅助根治性阴道子宫切除术、7例根治性腹式子宫切除术、2例LSC辅助根治性阴道宫颈切除术以及2例单独的LSC淋巴结清扫术(继发于阳性淋巴结)。平均肿瘤大小为2.5 cm。64个SLN中有19%位于不寻常部位,包括髂总(11%)、骶前(5%)和腹主动脉旁(3%)。阴性预测值为100%。联合技术在所有患者中均双侧检测到SLN。如果仅使用蓝色染料,该比例将降至67.5%,且与手术时间的延长呈负相关(-0.7;p = 0.002)。蓝色SLN的可视能力在30分钟内保持稳定,50分钟时完全消失。
腹腔镜SLN定位可新引入妇科肿瘤中心,具有较高的检测率和阴性预测值。SLN中蓝色染料的可视化是短暂的,这种负时间相关性可能解释了先前报道的该技术较低的检测率。临床试验注册:ClinicalTrials.gov,http://www.clinicaltrials.gov,NCT 00205010。